Identification, mapping, and engagement of key opinion leaders (KOLs) in life sciences & healthcare through our in-house panel make us the most preferred partner in the industry.
Key opinion leaders influence and drive the latest therapies and devices across the markets, their opinions on drugs/devices are based on sound research and make them the ideal drivers for any healthcare product company (drugs/devices/diagnostics).
At SGA, we help our clients identify such key opinion leaders who can guide our industry clients regarding the right connections, relationships, etc. This can lead to the creation of a broader disease ecosystem, wherein the client’s drug or device must compete and thrive.
SGA has a panel of KOLs spread across >30 sub-specialty and >15 hierarchies, which include CXO levels to senior managers and distributors. Our panelists guide us through a client’s product lifecycle and clinical trials and share the market sentiments, perceptions, and expectations. Our multilingual analysts can help you connect with these influencers in both non-English-speaking and English-speaking markets.
Why SGA
Industry leaders
SGA thrives by its brand promise Lifes Possible and is recognized as the trusted life sciences & healthcare business consulting and services provider company in the U.S.
12+ Languages
Multilingual capabilities include Mandarin, Cantonese, Korean, German, Spanish, Arabic, Bahasa, Hindi, Bengali, and English (U.S. & U.K.) experts (either in-house or partnerships).
Data-Driven Insights
With in-depth domain knowledge and proven capabilities of delivering monetizable insights, we deliver high-quality, efficient outputs.
End-To-End Solutioning
The in-house KOL capability of more than 700, along with in-house capabilities of primary market research, financial research, data analytics, engineering, IT, and ESG research and consulting, helps to present credible competitive information.
Whitepapers
Emergence of Novel Immune - Mediated Therapies
Immunotherapy has emerged as a promising treatment for cancer, with immune checkpoint inhibitors (ICIs) dominating the market. The market is projected to...
Whitepapers
Future Trends and Technological Advances in Vaccine and Disease Prevention
The introduction of vaccines for key diseases, such as meningococcal meningitis A, hepatitis E, and malaria, in recent years has helped to reduce mortality...
Whitepapers
Market Entry in 2023: Why Must You Also Look at Markets Other Than the US and Japan?
Due to dollar fluctuations and the likelihood of market recession, investors and manufacturers of medical devices and pharma are exploring new opportunities...
CASE STUDIES
We strongly believe in equal opportunity for all. Our research team consists of more females than males i.e., 55 % females, and consists of PhDs, M Pharms, D Pharms, Postgraduate in finance, Biotech postgraduates, and MBAs.
